 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12345678910111213...3839» |
- || Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal, Real-world evidence, Real-world: Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: an external validity analysis of 66,639 biologic users from the Italian VALORE project. (Pubmed Central) - Jan 17, 2024
In the real-world setting, certolizumab pegol was more commonly used by adult women with psoriasis/ankylosing spondylitis (F/M ratio: 1.8-1.9) compared to RCTs (F/M ratio: 0.5-0.6)...Furthermore, almost half (46.4%) of biologic users from RW settings would have been ineligible for inclusion in the respective indication-specific pivotal RCTs; the main reasons were: advanced age, recent history of cancer and presence of other concomitant IMIDs. These findings suggest that post-marketing surveillance of biologics should be prioritized for those patients.
- | Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: BIOTAPE: Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis (clinicaltrials.gov) - Jan 17, 2024
P4, N=15, Active, not recruiting, Sponsor: University Health Network, Toronto
These findings suggest that post-marketing surveillance of biologics should be prioritized for those patients. Recruiting --> Active, not recruiting | N=156 --> 15 | Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Dec 2023 --> Jul 2024
- | Journal: Therapeutic TNF Inhibitors Exhibit Differential Levels of Efficacy in Accelerating Cutaneous Wound Healing. (Pubmed Central) - Jan 16, 2024
In line with histologic assessments, proteomics analyses from healing wounds exposed to various TNF inhibitors revealed distinct and differential wound-healing signatures that may underlie the differential efficacy of these inhibitors in accelerating cutaneous wound healing. Taken together, these data revealed that TNF inhibitors exhibited differential levels of efficacy in accelerating cutaneous wound healing in the impaired wound-healing model in
- | Bimzelx (bimekizumab) / UCB
Journal: Bimekizumab (Bimzelx) for psoriasis. (Pubmed Central) - Jan 11, 2024
Taken together, these data revealed that TNF inhibitors exhibited differential levels of efficacy in accelerating cutaneous wound healing in the impaired wound-healing model in No abstract available
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Influence of rheumatoid factor on serum drug levels of tumour necrosis factor inhibitors with different structures in rheumatoid arthritis. (Pubmed Central) - Jan 10, 2024
In this real word data evaluation, CZP serum levels were independent of RF levels in patients however patients with high baseline RF levels who obtained IFX or ADL had lower serum drug levels at 6 months than baseline RF-negative patients. In addition, secondary non-response was more frequent in patients with high RF levels treated with IFX and ADL.
- | Trial completion date, Trial primary completion date: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response (clinicaltrials.gov) - Jan 3, 2024
P3, N=400, Recruiting, Sponsor: University of Nebraska
In addition, secondary non-response was more frequent in patients with high RF levels treated with IFX and ADL. Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2025 --> Mar 2026
- Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / AbbVie
SAFETY OF ANTI-TUMOR NECROSIS FACTOR AGENTS COMPARED TO USTEKINUMAB AND VEDOLIZUMAB IN ELDERLY PATIENTS WITH ULCERATIVE COLITIS (Bellagio Ballroom - Bellagio Las Vegas) - Dec 24, 2023 - Abstract #CCCongress2024CCCongress_361;
While these medications have all demonstrated general efficacy and safety in UC, this study aims to examine the long-term comparative safety of anti-TNF agents with vedolizumab and ustekinumab in elderly patients with UC.The Research Network on TriNetX database was accessed on September 26, 2023, to identify patients at least 65 old who were diagnosed with UC: the first cohort included patients prescribed anti-TNF agents (included adalimumab, certolizumab pegol, golimumab, and infliximab) and the second cohort included patients prescribed either vedolizumab or ustekinumab. In elderly patients with UC, ustekinumab or vedolizumab are safer treatment options compared to anti-TNF therapy.
- Humira (adalimumab) / AbbVie
LOWER MORTALITY RISK WITH COMBINATION THERAPY WITH ANTI-TNF THERAPY AND THRIOPURINE COMPARED TO THIOPURINE ALONE IN ELDERLY PATIENTS WITH UC (Bellagio Ballroom - Bellagio Las Vegas) - Dec 24, 2023 - Abstract #CCCongress2024CCCongress_359;
The study findings highlight the risks of thiopurine use in patients over the age of 65 given the significantly higher 10-year mortality risk in thiopurine monotherapy-treated patients. The results also suggest that combination therapy with thiopurine and anti-TNF therapies - despite utilization in patients with more active disease indicators - is not associated with an additive risk in terms of infection and mortality in elderly patients.
- BIOLOGICS AND SMALL MOLECULES USED IN IBD MIMICS: HIGHLIGHTING THE IMPORTANCE OF DIAGNOSIS CONFIRMATION (Bellagio Ballroom - Bellagio Las Vegas) - Dec 24, 2023 - Abstract #CCCongress2024CCCongress_342;
14 were treated with one biologic, 5 with two biologics, and 6 with three or more biologics.The biologics used in the management of these IBD mimics included infliximab (n=21), vedolizumab (n=12), adalimumab (n=11), ustekinumab (n=6), and certolizumab (n=1).Of the 25 cases of biologic usage without definitive confirmation of IBD, 6 ended up with a diagnosis where biologics were an appropriate treatment for the mimic. These mimics included drug-induced colitis (n=3), Behcet
- Unveiling the impact on in utero exposure to biologic treatments for inflammatory bowel disease (IBD) on children's psychomotor development: Insights from the DUMBO registry of GETECCU. (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_828;
Conclusion In the multicenter, prospective DUMBO registry, the exposure to biologics for the treatment of IBD in utero (including anti-TNF and non-anti-TNF agents) did not impair the psychomotor development of the children. Our findings support the safety of these drugs and reinforce the recommendation to continue them during pregnancy.
- Spevigo (spesolimab-sbzo) / Boehringer Ingelheim, Cimzia (certolizumab pegol) / Astellas, UCB
Identification of IL36RN missense mutations in Crohn (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_704;
Spesolimab was made available on the basis of an out of scope request. Boehringer Ingelheim was given the opportunity to review this abstract as a courtesy.
- | Journal: Overview and therapy update Crohn's disease (Pubmed Central) - Dec 18, 2023
Moreover, the Janus kinase-1 inhibitor upadacitinib has been available for the treatment of CD in the EU since 2023...Nevertheless, CD remains an incurable disease and so far, for all existing treatments only a fraction of patients responds to the therapy. Therefore, the development of new therapies should continue.
- | Journal: Long-term retention rates of (Pubmed Central) - Dec 16, 2023
The main reason for discontinuation was secondary inefficacy. Regarding adalimumab, secondary inefficacy was linked to the extent of arthritis upon treatment initiation.
- | Bimzelx (bimekizumab) / UCB
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden. (Pubmed Central) - Dec 11, 2023
Regarding adalimumab, secondary inefficacy was linked to the extent of arthritis upon treatment initiation. In bDMARD-na
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open, Trial initiation date: CERTIFY: Certolizumab in Recurrent Implantation Failure (RIF) (clinicaltrials.gov) - Dec 11, 2023
P3, N=161, Recruiting, Sponsor: Assistance Publique - H
In bDMARD-na Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Nov 2023
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) - Dec 7, 2023
P3, N=193, Active, not recruiting, Sponsor: UCB BIOSCIENCES GmbH
Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Nov 2023 Trial primary completion date: Dec 2023 --> Mar 2024
- | nipocalimab (M281) / J&J
Phase classification: DAISY: A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 6, 2023
P2, N=85, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Dec 2023 --> Mar 2024 Phase classification: P2a --> P2
- |||||| Enrollment open, Trial initiation date: COMMIT: Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success (clinicaltrials.gov) - Dec 6, 2023
P=N/A, N=240, Recruiting, Sponsor: Insel Gruppe AG, University Hospital Bern
Phase classification: P2a --> P2 Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Sep 2023
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Clinical problems in Medical Mycology: Problem number 56 (Pubmed Central) - Dec 4, 2023
We present the case of a twenty six year-old woman with rheumatoid arthritis, treated with certolizumab...Histoplasma capsulatum PCR test and urinary antigen were positive, so an antifungal treatment with voriconazole was started...With this measure the patient progressed favorably. The test of urinary Histoplasma capsulatum antigen and PCR amplification were key to make a diagnosis and also for a follow-up.
- || Review, Journal: Intra-articular injections of biological disease-modifying anti-rheumatic drugs in inflammatory arthropathies: an up-to-date narrative review. (Pubmed Central) - Dec 4, 2023
The IA use of bDMARDs seems to be weakly effective in the management of resistant synovitis and not superior to GCs injections. The treatment's main limit appears to be the poor persistence of the compound in the joint.
- | Journal: Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure database. (Pubmed Central) - Dec 4, 2023
The epidemiological characteristics of patients with rheumatic diseases and viral hepatitis are essential for effective patient management. This study provided the most recent epidemiological characteristics from the prospective TReasure database, one of the comprehensive registries in rheumatology practice.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: Zr-89 Cimzia PET Imaging Rheumatoid Arthritis (clinicaltrials.gov) - Dec 4, 2023
P1, N=10, Suspended, Sponsor: Robert Flavell, MD, PhD
This study provided the most recent epidemiological characteristics from the prospective TReasure database, one of the comprehensive registries in rheumatology practice. Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
- | Herceptin (trastuzumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Mucosal absorption of antibody drugs enhanced by cell-penetrating peptides anchored to a platform of polysaccharides. (Pubmed Central) - Nov 20, 2023
Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025 A similar result was observed under substitution of ranibizumab with certolizumab pegol (91
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: CIMcare: A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO) (clinicaltrials.gov) - Nov 19, 2023
P3, N=150, Recruiting, Sponsor: UCB Biopharma SRL
A similar result was observed under substitution of ranibizumab with certolizumab pegol (91 Trial completion date: Aug 2029 --> Aug 2034 | Trial primary completion date: Sep 2024 --> Sep 2029
- | Journal: Prevalence of metabolic syndrome and chronic inflammation in psoriasis before and after biologic therapy: a prospective study. (Pubmed Central) - Nov 16, 2023
Moreover, after 6 months, the number of patients meeting the diagnostic criteria for metabolic syndrome and chronic inflammation was significantly lower than at baseline (p<0.001). According to our results, biologic therapies improve the overall metabolic and inflammatory profiles of psoriasis patients, the most significant ameliorations being noticed for serum HDL, CRP, and ESR.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach. (Pubmed Central) - Nov 9, 2023
A mixed hidden-Markov model (MHMM) was developed to characterize the underlying (hidden) formation of ADA against the biologic, using certolizumab pegol (CZP), as a test drug...Individual state sequences obtained using a Viterbi algorithm suggested that the model was able to determine the start of ADA production for each individual, being a more assay-independent methodology than traditional population PK. The model serves as a basis for identification of covariates influencing the ADA formation, and thus has the potential to identify aspects that minimize its impact on PK and/or efficacy.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date: Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) - Nov 8, 2023
P3, N=193, Active, not recruiting, Sponsor: UCB BIOSCIENCES GmbH
The model serves as a basis for identification of covariates influencing the ADA formation, and thus has the potential to identify aspects that minimize its impact on PK and/or efficacy. Trial completion date: Dec 2023 --> Mar 2024
- || Trial completion date, Trial primary completion date, Immunomodulating: COVER: COVID-19 VaccinE Response in Rheumatology Patients (clinicaltrials.gov) - Nov 8, 2023
P4, N=1000, Recruiting, Sponsor: Jeffrey Curtis
Trial completion date: Dec 2023 --> Mar 2024 Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: May 2023 --> Feb 2024
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Certolizumab treatment of localized pyoderma gangrenosum in a pregnant patient. (Pubmed Central) - Nov 4, 2023
In addition, we reviewed the literature and compared the current treatment efficiency in the treatment of PG. Certolizumab may be a promising therapeutic option for patients with severe PG.
- A Translational Approach to Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman Disease (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_5336;
We utilized a translational research approach including experimental and unbiased machine learning approaches to identify TNF as a novel therapeutic target that we inhibited to treat a highly refractory iMCD patient. Together, our data suggest that over-production of TNF, in part by activated T cells, promotes iMCD pathogenesis and highlight that further research is needed into TNF inhibition as a potential treatment strategy for iMCD.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis. (Pubmed Central) - Nov 1, 2023
Our study provided patient specific QSP models that reproduced clinical and molecular efficacy features, supporting the use of computational methods as modelling strategy to explore drug response variability. This might shed light on the differences in drug efficacy in diverse subpopulations, especially useful in complex diseases such as psoriasis, through the generation of mechanistically based hypotheses.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Persistence of Biologics in the Treatment of Psoriatic Arthritis (Psa): Data From a Large Hospital Based Longitudinal Cohort. (Pubmed Central) - Oct 23, 2023
Persistence in taking biologics depends on whether the biologic was used as first or second treatment. Depression and anxiety, higher tender joint count, and older age lead to drug discontinuation.
- | Journal: Formation and clearance of TNF-TNF inhibitor complexes during TNF inhibitor treatment. (Pubmed Central) - Oct 20, 2023
Depression and anxiety, higher tender joint count, and older age lead to drug discontinuation. Differences in TNFi structure profoundly impact the clearance of TNF, while it is unlikely that TNF itself significantly contributes to target-mediated drug disposition of TNFi.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy (clinicaltrials.gov) - Oct 18, 2023
P2, N=55, Recruiting, Sponsor: David Ware Branch
Differences in TNFi structure profoundly impact the clearance of TNF, while it is unlikely that TNF itself significantly contributes to target-mediated drug disposition of TNFi. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Journal: Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment. (Pubmed Central) - Oct 14, 2023
Vedolizumab use was associated with an increased risk of nephrolithiasis. The use of two or more biologic drugs also increased the risk compared to no biologic treatment.
- | Journal, Immunomodulating: Effect of Immunosuppressive or Immunomodulatory Agents on Severe COVID-19 Outcomes: A Population-Based Cohort Study. (Pubmed Central) - Oct 11, 2023
Current use of MMF and glucocorticoids were associated with an increased risk of severe COVID-19 outcomes compared with nonuse. These results emphasize the variety of circumstances of patients taking IIAs.
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Cimzia (certolizumab pegol) / Astellas, UCB
Review, Journal: Anti-TNF-? induced paradoxical psoriasis in patients with ankylosing spondylitis: a systematic review. (Pubmed Central) - Oct 9, 2023
PP is an uncommon adverse reaction to TNFi treatment in AS patients and responds well to drug withdrawal. More large data studies need to be conducted though, to shed light on PP nature and management.
- Humira (adalimumab) / AbbVie
Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Psoriatic Arthritis in Japan (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4219;
While treatment switch rates varied across bDMARDs, discontinuation rates were lowest for RZB at each timepoint that was examined. Hazards of switching or discontinuation relative to RZB were generally higher across most bDMARDs, indicating higher treatment persistence rates for RZB.
- Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNF? Inhibitors (IL-17Ai or TNFi) (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4213;
Persistence to therapy can be especially important in chronic, progressive diseases like PsA where patients will likely have to change treatment regimens over the course of disease. Results from this study indicate that IL-17Ai biologics can represent a viable, long-lived treatment choice even among patients with prior biologic experience and high comorbidity burden.
- Rinvoq (upadacitinib) / AbbVie
Upadacitinib in Refractory Psoriatic Arthritis. Multicenter Study of 134 Patients in Clinical Practice (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4210;
In addition, they received the following ts-DMARDs: Tofacitinib (n=29), Apremilast (27), Filgotinib (1). UPA at baseline was associated with: a) prednisone (43.3%; mean dose 8.3
- Exploring Metabolite Markers Associated with Treatment Response of Biologic Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis Patients (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4190;
Patients were treated with either TNFi (n = 20; infliximab, adalimumab, etanercept, certolizumab or golimumab) or IL-17Ai (n = 20; secukinumab or ixekizumab). The identification of cotinine
- Humira (adalimumab) / AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4120;
P4
CZP-treated patients with RA and high titer RF had similar drug concentrations and clinical responses to patients with RA and low titer RF, a pattern not observed in ADA-treated patients. These data, together with previous reports where CZP showed consistent efficacy irrespective of BL RF titer, 6,7 suggest CZP may be a suitable therapy for patients with RA and high RF titer.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR) (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4113;
These increases were observed primarily in RF, ACPA, ANA positive patients. Our data provide a potential mechanistic link between glucocorticoid treatment and cardiovascular disease.
- Actemra IV (tocilizumab) / Roche, JW Pharma
Prevalence and Risk Factors of Pneumocystis Jirovecii Colonization in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors and Tocilizumab (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4101;
Tocilizumab and prednisolone might be associated witha higher risk of P. jirovecii colonization in patients with RA. Table 1 Baseline demographics of patients Table 2 Logistic regression analysis for factors associated with Pneumocystis jirovecii colonization Table 3 Characteristics of 8 patients with Pneumocystis jirovecii colonization
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Beh (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3624;
CZP appears effective even in patients with inadequate response to ADA and/or IFX. N.
- Humira (adalimumab) / AbbVie
De Novo Manifestations During Adalimumab Treatment in Beh (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3622;
Majority of these (75%) were major organ involvement, mainly vascular involement. of the patients developed posterior uveitis, the 2 patients with uveitis developing during ADA had anterior uveitis that was controlled with topical agents.
- Paternal Effects of Anti-TNFs in Inflammatory Arthritis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3436;
Among the male patients taking anti-TNF treatment, infertility due to paternal origin does not seem to be a major issue according to our limited data. Anti-TNF treatment thus seems to be safe with regards to fertility in male patients.
- Continuing Biologic DMARDs During Pregnancy in Women with Rheumatic Disease Was Not Associated with Increased Unfavorable Pregnancy Outcomes, Serious Infections, and Adverse Effects of Vaccination (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3434;
It was suggested that the continuation of bDMARDs may be an effective treatment option for rheumatic diseases during pregnancy. Larger number of examinations are needed as to how long to continue bDMARDs during pregnancy.
- Prevalence and Incidence of Paradoxical Side-effects of TNF-? Inhibitors: A Cross-sectional Study (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3194;
Larger number of examinations are needed as to how long to continue bDMARDs during pregnancy. Incidence of PSE per 1000 patient-years was 7.9 (95% CI : 4.4
- Exploring the Risk of Demyelination Associated with TNF Alpha Inhibitors: Analysis of the FDA Adverse Event Reporting System (FAERS) (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3183;
While a temporal relationship between anti-TNF-a treatment and demyelinating events is suggested, the overall number of published cases is small compared to the total number of treated patients. In most cases, demyelination either progressed slowly or resolved after discontinuing anti-TNF-a therapy, indicating a potential protective effect or short-lasting harmful impact in patients already suffering from latent MS.